Supportive treatments

Acupuncture for reduction of symptom burden in multiple myelomapatients undergoing autologous hematopoietic stem cell transplantation: a randomized sham-controlled trial. Deng G et al. Support Care Cancer. 2017 Sep 17. doi: 10.1007/s00520-017-3881-7. [Epub ahead of print]. The treatment of paraprotein-related kidney disease. Hutchison CA et al. Curr Opin Nephrol Hypertens. 2017 Sep 6. doi: 10.1097/MNH.0000000000000369. [Epub ahead of print]. Surgical Roles for Spinal…

Details

General

Chimeric antigen receptor T-cell therapy – assessment and management of toxicities. Neelapu SS et al. Nat Rev Clin Oncol. 2017 Sep 19. doi: 10.1038/nrclinonc.2017.148. [Epub ahead of print]. Chimeric Antigen Receptor T-cell Therapies for Multiple Myeloma. Mikkilineni L et al. Blood. 2017 Sep 19. pii: blood-2017-06-793869. doi: 10.1182/blood-2017-06-793869. [Epub ahead of print]. Checking in: T cells against multiple myeloma. Kumar SK. Blood. 2017 Sep 7;130(10):1175-1176.…

Details

Emerging Treatments

A Phase1b Dose Escalation Study of Recombinant Circularly Permuted TRAIL in Patients With Relapsed or Refractory Multiple Myeloma. Hou J et al. Am J Clin Oncol. 2017 Sep 19. doi: 10.1097/COC.0000000000000404. [Epub ahead of print]. A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma. Cavenagh J et al. Br J Cancer. 2017 Sep…

Details

Diagnostic techniques and prognostic indicators

Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials. Bhutani M et al. Lancet Haematol. 2017 Sep;4(9):e443-e451. doi: 10.1016/S2352-3026(17)30143-6. Detection of Circulating Plasma Cells in Multiple Myeloma. Alix-Panabières C et al. Clin Chem. 2017 Sep 18. pii: clinchem.2017.275446. doi: 10.1373/clinchem.2017.275446. [Epub ahead of print]. Quantitative analysis of 18F-NaF dynamic PET/CT cannot differentiate malignant from benign lesions in multiple myeloma. Sachpekidis C et al. Am J Nucl Med Mol Imaging. 2017 Sep…

Details

Current treatments

Stem cell mobilization in patients with dialysis-dependent multiple myeloma: Report of the Polish Myeloma Study Group. Waszczuk-Gajda A et al. J Clin Apher. 2017 Sep 18. doi: 10.1002/jca.21584. [Epub ahead of print]. Autologous hematopoietic cell transplantation for multiple myelomapatients with renal insufficiency: a center for international blood and marrow transplant research analysis. Mahindra A et al. Bone Marrow Transplant. 2017 Sep 18. doi: 10.1038/bmt.2017.198. [Epub…

Details

Complications of myeloma and its treatments

Plasma Cell Infiltration of the Kidney as a Manifestation of Myeloma: A Report of Three Cases. Kaur T et al. Indian J Nephrol. 2017 Sep-Oct;27(5):395-398. doi: 10.4103/ijn.IJN_215_16. Incidence of Contrast-Induced Nephropathy in Patients with Multiple Myeloma Undergoing Contrast-Enhanced Procedures. Crowley MP et al. Pathol Oncol Res. 2017 Sep 13. doi: 10.1007/s12253-017-0300-9. [Epub ahead of print]. Multiple Myeloma Presenting as Massive Amyloid Deposition in a Parathyroid…

Details

Biology and genetics

Inhibition of the deubiquitinase USP5 leads to c-Maf protein degradation and myeloma cell apoptosis. Wang S et al. Cell Death Dis. 2017 Sep 21;8(9):e3058. doi: 10.1038/cddis.2017.450. The non-canonical poly(A) polymerase FAM46C acts as an onco-suppressor in multiple myeloma. Mroczek S et al. Nat Commun. 2017 Sep 20;8(1):619. doi: 10.1038/s41467-017-00578-5. Dihydroorotate dehydrogenase Inhibitors Target c-Myc and Arrest Melanoma, Myeloma and Lymphoma cells at S-phase. Dorasamy MS et al. J…

Details

IMWG study demonstrates benefit of whole body CT imaging in myeloma patients

A recent study, conducted by the International Myeloma Working Group (IMWG), has demonstrated the benefits of whole body computed tomography (WBCT) compared to conventional skeletal survey (CSS) for identifying osteolytic lesions in myeloma. The study, published in Blood Cancer Journal, found that WBCT is more sensitive than CSS in detecting skeletal lesions, with 20-25% patients…

Details

Myeloma UK funded research demonstrates impact of neutral tumour evolution on myeloma patient outcome

A study, funded by Myeloma UK, has demonstrated that neutral tumour evolution in myeloma is associated with poorer prognosis. Neutral evolution is the term used to describe evolution caused by random genetic mutations and are normally considered to be neither beneficial nor detrimental to survival. However, in this study, such tumours conferred a worse prognosis…

Details